GLSI — Greenwich LifeSciences, Inc. stock price, charts and financials
QT15Greenwich LifeSciences, Inc.Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
14.35
+0.81+5.98%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 14.68M | Perf Week | 6.69% |
| Market Cap | 210.63M | Forward P/E | - | EPS next Y | -1.17 | Insider Trans | 0.10% | Shs Float | 7.38M | Perf Month | -29.79% |
| Enterprise Value | 204.63M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 19.88% | Perf Quarter | -34.71% |
| Income | -19.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 10.29 | Perf Half Y | -55.11% |
| Sales | 0.00 | P/B | 37.31 | EPS next Y | 15.52% | ROA | -207.10% | Short Interest | 1.47M | Perf YTD | -31.70% |
| Book/sh | 0.00 | P/C | 35.10 | EPS next 5Y | - | ROE | -941.06% | 52W High | 34.10 -57.92% | Perf Year | 29.40% |
| Cash/sh | 0.41 | P/FCF | - | EPS past 3/5Y | - | ROIC | -415.38% | 52W Low | 7.78 84.45% | Perf 3Y | 62.15% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 9.40% 10.45% | Perf 5Y | -64.97% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -2.48% | Oper. Margin | 0.00% | ATR (14) | 1.72 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.01 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 39.27 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.01 | EPS Q/Q | -95.00% | SMA20 | -8.58% | Beta | 1.42 | Target Price | 50.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -29.79% | Rel Volume | 0.96 | Prev Close | 13.54 |
| Employees | 13 | LT Debt/Eq | - | Earnings | Aug 13 | SMA200 | -29.19% | Avg Volume | 157.56K | Price | 14.35 |
| IPO Date | Sep 25, 2020 | Option/Short | No / Yes | EPS/Sales Surpr. | -18.18% - | Net Debt/EBITDA | 0.48 | Volume | 150,860 | Change | 5.98% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Dec-30-25 | Reiterated | HC Wainwright & Co. | Buy | $50 |
Latest News
Jul-22-26
Jul-22-2606:00AM
Jul-21-26
Jul-21-2601:03PM
Jul-20-26
Jul-16-26
Jul-16-2607:31AM
07:30AM
03:33AM
Greenwich LifeSciences The Overlooked Needseekingalpha.com
Jul-09-26
Jul-09-2606:04AM
Company
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | |
| Research and Development | 17 | 15 | 8 | 6 | 4 | 1 | 3 | 1 | 1 | |
| Other Operating Expense | 0 | 1 | -1 | 0 | 0 | 0 | -1 | 1 | 1 | |
| Operating Income | -19 | -18 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | -19 | -17 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -19 | -17 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| Net Income From Continuing Operations | -19 | -17 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| Net Income | -19 | -17 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| EPS (Recurring) | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 | |
| EPS (Basic, Before Extraordinaries) | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 | |
| EPS (Diluted) | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 | |
| EBITDA | -19 | -17 | -9 | -8 | -5 | -2 | -3 | -2 | -2 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 14 | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | |
| Market Capitalization | 294 | 146 | 137 | 198 | 316 | 474 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO | Jul 29 '26 | Buy | 13.10 | 700 | 9,170 | 5,611,402 | Jul 30 |
| Patel Snehal | CEO and CFO | Jul 28 '26 | Buy | 13.59 | 1,500 | 20,385 | 5,610,702 | Jul 30 |
| Patel Snehal | CEO and CFO | Jul 27 '26 | Buy | 13.62 | 1,500 | 20,430 | 5,609,202 | Jul 29 |
| Patel Snehal | CEO and CFO | Jul 24 '26 | Buy | 12.88 | 1,100 | 14,168 | 5,607,702 | Jul 27 |
| Patel Snehal | CEO and CFO | Jul 23 '26 | Buy | 13.14 | 2,500 | 32,850 | 5,606,602 | Jul 27 |
| Patel Snehal | CEO and CFO | Jan 13 '26 | Buy | 29.83 | 1,800 | 53,694 | 5,604,102 | Jan 15 |
| Patel Snehal | CEO and CFO | Jan 12 '26 | Buy | 27.54 | 2,900 | 79,866 | 5,602,302 | Jan 14 |
| Patel Snehal | CEO and CFO | Dec 31 '25 | Buy | 21.36 | 4,300 | 91,848 | 5,599,402 | Jan 05 |
| Patel Snehal | CEO and CFO | Dec 30 '25 | Buy | 21.73 | 2,900 | 63,017 | 5,595,102 | Jan 02 |
| Patel Snehal | CEO and CFO | Dec 18 '25 | Buy | 12.62 | 4,100 | 51,742 | 5,592,202 | Dec 19 |
| Patel Snehal | CEO and CFO | Nov 25 '25 | Buy | 8.37 | 4,600 | 38,502 | 5,588,102 | Nov 28 |
| Patel Snehal | CEO and CFO | Nov 07 '25 | Buy | 8.43 | 10,600 | 89,358 | 5,583,502 | Nov 12 |
| Patel Snehal | CEO and CFO | Oct 31 '25 | Buy | 9.26 | 2,300 | 21,298 | 5,572,902 | Nov 04 |
| Patel Snehal | CEO and CFO | Apr 25 '25 | Buy | 9.88 | 3,600 | 35,568 | 5,570,602 | Apr 29 |
| Patel Snehal | CEO and CFO | Apr 17 '25 | Buy | 8.98 | 5,400 | 48,492 | 5,567,002 | Apr 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.